These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27758143)

  • 21. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
    Scionti I; Michelacci F; Pasello M; Hattinger CM; Alberghini M; Manara MC; Bacci G; Ferrari S; Scotlandi K; Picci P; Serra M
    Ann Oncol; 2008 Aug; 19(8):1500-1508. PubMed ID: 18385200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of pharmacogenetics in the treatment of osteosarcoma.
    Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
    Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaphylaxis during the first course of high-dose methotrexate: a case report and literature review.
    Pugi A; Benemei S; Vietri M; Tondo A; Calvani AM; Mugelli A; Vannacci A; Lapi F
    J Clin Pharm Ther; 2012 Apr; 37(2):245-8. PubMed ID: 21569069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on emerging drugs in osteosarcoma: towards tailored therapies?
    Hattinger CM; Patrizio MP; Magagnoli F; Luppi S; Serra M
    Expert Opin Emerg Drugs; 2019 Sep; 24(3):153-171. PubMed ID: 31401903
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
    Dervieux T; Greenstein N; Kremer J
    Arthritis Rheum; 2006 Oct; 54(10):3095-103. PubMed ID: 17009228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD; Messenger M; Taplin SC
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies targeting proteins that regulate folate and reduced folate transport.
    Trippett TM; Bertino JR
    J Chemother; 1999 Feb; 11(1):3-10. PubMed ID: 10078775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folate and antifolate pharmacology.
    Kamen B
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focal skin toxicity related to methotrexate sparing psoriatic plaques.
    Truchuelo T; Alcántara J; Moreno C; Vano-Galván S; Jaén P
    Dermatol Online J; 2010 Jun; 16(6):16. PubMed ID: 20579471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacogenetics of methotrexate.
    Castaldo P; Magi S; Nasti AA; Arcangeli S; Lariccia V; Alesi N; Tocchini M; Amoroso S
    Curr Drug Metab; 2011 Mar; 12(3):278-86. PubMed ID: 21470106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New analogues of methotrexate].
    Yoshimura A
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2133-9. PubMed ID: 1444480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.
    Neradil J; Pavlasova G; Sramek M; Kyr M; Veselska R; Sterba J
    Oncol Rep; 2015 May; 33(5):2169-75. PubMed ID: 25739012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
    Pongracz N; Kelaridis T; Ritschl P
    Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and antitumor activity of a polymeric derivative of methotrexate.
    Zhou G; Cheng X; Wu S; Jiang X; Shi X; Chen J; Zhang J; Zhao J
    Am J Med Sci; 2012 Oct; 344(4):294-9. PubMed ID: 22885620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted expression of human folylpolyglutamate synthase for selective enhancement of methotrexate chemotherapy in osteosarcoma cells.
    Bienemann K; Staege MS; Howe SJ; Sena-Esteves M; Hanenberg H; Kramm CM
    Cancer Gene Ther; 2013 Sep; 20(9):514-20. PubMed ID: 23949282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allergic reaction to high-dose methotrexate.
    Postovsky S; Elhasid R; Ben-Barak A; Levin K; Ben Arush MW
    Med Pediatr Oncol; 2000 Aug; 35(2):131-2. PubMed ID: 10918237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.